Puberty and breeding performance of beef heifers developed at different rates of gain

Crossbred heifers (546 lb initial body weight) were developed in drylot and limit-fed a corn, corn silage diet to gain .5 (n = 14), 1.0 (n = 15), 1.5 (n = 14), or 2.0 lb/d (n = 15) from Dec. 7, 1992 until the onset of the breeding season, May 3, 1993. Actual daily gains averaged 1.0, 1.4, 1.8, and 2.1 lb/d, respectively. Age at puberty was not affected by feeding treatment. At the onset of the breeding season, nutritional treatment had a linear effect on body condition score, ribeye fat thickness (both P<.01), and reproductive tract score (P<.05), all increasing with increasing rate of gain. Nutritional treatment had a quadratic effect on pelvic area (P<.05), which averaged 190.6, 201.6, 206.5, and 205.3 cm2 for heifers fed to gain .5, 1.0, 1.5, and 2.0 lb/d, respectively. At the conclusion of the development period, estrus was synchronized, and heifers were inseminated artificially at estrus for 45 days and, if open, mated naturally for another 17 d. Overall pregnancy rates were similar among heifers fed to gain .5, 1.0, and 1.5 lb/d (92.9, 93.3, and 92.9%, respectively), and all tended to be greater (P<.09) than the rate for heifers fed to gain 2.0 lb/d (66.7%). In summary, NRC recommendations underestimated gain of limit-fed heifers at lower predicted rates of gain. Thus, even though heifers fed to gain only .5 lb/d had lower body condition scores and reproductive tract scores at the onset of the breeding season, their actual body weight gains (1.0 lb/d) were sufficient for normal onset of puberty and subsequent conception. In addition, heifers fed to achieve relatively high rates of gain (2.0 lb/d) during development may have had impaired fertility

Timing of gain does not alter puberty and reproductive performance of beef heifers fed a high-roughage diet

Eighty crossbred heifers (549 lb initial body weight) were developed in drylot and limit-fed a forage sorghum silage diet predicted to produce gains of either 1 lb/day for the entire developmental period (EVENGAIN) or .25 lb/day for the first two-thirds of the period followed by 2 lb/day during the last third (LATEGAIN). Treatments began on November 7, 1994 and continued until April 24, 1995 (onset of the breeding season). Actual daily gains over the entire feeding period averaged 1.18 and 1.10 lb/day for EVENGAIN and LATEGAIN heifers, respectively. Age and weight at puberty were not affected by feeding treatment. Body condition score, frame score, and pelvic area were similar at the end of the experiment regardless of growth regimen. At the conclusion of the 168-day feeding period, estrus was synchronized using two injections of prostaglandin F2 , and heifers were inseminated artificially during a 45-day breeding season. Open heifers were mated naturally for an additional 15 days. First service and overall pregnancy rates were similar between treatments. In summary, timing of gain did not affect the onset of puberty or breeding performance. These data indicate that bee f producers may be able to utilize low quality feedstuffs early in heifer development without adversely affecting reproductive performance. Because feed inputs are major costs for developing beef heifers, such a management alternative may decrease costs

Supplemental chromium and revaccination effects on performance and health of newly weaned calves

Two trials were conducted to evaluate the effects of chromium (Cr) supplementation (4 mg/hd/day in a yeast form) or no supplementation, with or without revaccination with a modified live viral vaccine at 9 days postweaning o n performance, health, and ability to withstand an IBR challenge infection. In Trial 1, Cr supplementation had no effect on performance of newly weaned calves in a 28-day receiving study, but reduced the incidence of respiratory disease by 37%. Revaccinati on depressed dry matter intake and had no effect on animal health. In trial 2, blood plasma levels of cortisol and ACTH (stress hormones ) were measured at 6 and 26 days postweaning. Cortisol levels were unaffected by treatment or by time after weaning. Plasma ACTH conc e ntrations were lower at 26 vs 6 days postweaning, and were reduced at 26 days by revaccination. Despite some slight differences in rectal temperature, treatment did not appear to affect the animals\u27 ability to withstand a live IBR challenge. We concluded that supplemental Cr was beneficial in reducing the incidence of bovine respiratory disease, although mediation of stress hormones was not involved. Revaccination of newly weaned calves with a modified live viral vaccine showed no performance or health benefit

A randomised controlled trial and cost-effectiveness evaluation of 'booster' interventions to sustain increases in physical activity in middle-aged adults in deprived urban neighbourhoods

Background: More evidence is needed on the potential role of 'booster' interventions in the maintenance of increases in physical activity levels after a brief intervention in relatively sedentary populations. Objectives: To determine whether objectively measured physical activity, 6 months after a brief intervention, is increased in those receiving physical activity 'booster' consultations delivered in a motivational interviewing (MI) style, either face to face or by telephone. Design: Three-arm, parallel-group, pragmatic, superiority randomised controlled trial with nested qualitative research fidelity and geographical information systems and health economic substudies. Treatment allocation was carried out using a web-based simple randomisation procedure with equal allocation probabilities. Principal investigators and study statisticians were blinded to treatment allocation until after the final analysis only. Setting: Deprived areas of Sheffield, UK. Participants: Previously sedentary people, aged 40-64 years, living in deprived areas of Sheffield, UK, who had increased their physical activity levels after receiving a brief intervention. Interventions: Participants were randomised to the control group (no further intervention) or to two sessions of MI, either face to face ('full booster') or by telephone ('mini booster'). Sessions were delivered 1 and 2 months post-randomisation. Main outcome measures: The primary outcome was total energy expenditure (TEE) per day in kcal from 7-day accelerometry, measured using an Actiheart device (CamNtech Ltd, Cambridge, UK). Independent evaluation of practitioner competence was carried out using the Motivational Interviewing Treatment Integrity assessment. An estimate of the per-participant intervention costs, resource use data collected by questionnaire and health-related quality of life data were analysed to produce a range of economic models from a short-term NHS perspective. An additional series of models were developed that used TEE values to estimate the long-term cost-effectiveness. Results: In total, 282 people were randomised (control = 96; mini booster = 92, full booster = 94) of whom 160 had a minimum of 4 out of 7 days' accelerometry data at 3 months (control = 61, mini booster = 47, full booster = 52). The mean difference in TEE per day between baseline and 3 months favoured the control arm over the combined booster arm but this was not statistically significant (-39 kcal, 95% confidence interval -173 to 95, p = 0.57). The autonomy-enabled MI communication style was generally acceptable, although some participants wanted a more paternalistic approach and most expressed enthusiasm for monitoring and feedback components of the intervention and research. Full boosters were more popular than mini boosters. Practitioners achieved and maintained a consistent level of MI competence. Walking distance to the nearest municipal green space or leisure facilities was not associated with physical activity levels. Two alternative modelling approaches both suggested that neither intervention was likely to be cost-effective. Conclusions: Although some individuals do find a community-based, brief MI 'booster' intervention supportive, the low levels of recruitment and retention and the lack of impact on objectively measured physical activity levels in those with adequate outcome data suggest that it is unlikely to represent a clinically effective or cost-effective intervention for the maintenance of recently acquired physical activity increases in deprived middle-aged urban populations. Future research with middle-aged and relatively deprived populations should explore interventions to promote physical activity that require less proactive engagement from individuals, including environmental interventions

Influence of L-carnitine on litter characteristics from gilts harvested at day 40, 55, and 70 of gestation

Swine research, 2005 is known as Swine day, 2005A total of 59 gilts were used to determine the effects of supplemental L-carnitine on reproductive performance. Experimental treatments were arranged in a 2 × 3 factorial with main effects of L-carnitine (0 or 50 ppm) and day of gestation (40, 55, or 70). All gilts received a constant feed allowance of 3.86 lb/day and a top-dress containing either 0 or 88 mg of L-carnitine, starting on the first day of breeding and continuing until the day of harvest. Total litter size, total litter weight, and crown-to-rump length of fetuses were not different (P>0.10) between treatments at any gestation length. By d 70 of gestation, average fetus weight was heavier (P = 0.06) for fetuses from gilts fed L-carnitine, compared with fetuses from gilts fed the control diet. In addition, at d 70, fetal insulin-like growth factor- II (IGF-II) concentrations were lower (P = 0.09) for fetuses from gilts fed L-carnitine than for fetuses from gilts fed the control diet. Feeding L-carnitine may have decreased fetal IGF-II, therefore increasing cell proliferation and delaying cell differentiation. These results show that providing supplemental Lcarnitine to gestating gilts has beneficial effects on average fetal weight, possibly observed because of its ability to reduce fetal IGF-II concentrations

Warming the early Earth - CO2 reconsidered

Despite a fainter Sun, the surface of the early Earth was mostly ice-free. Proposed solutions to this so-called "faint young Sun problem" have usually involved higher amounts of greenhouse gases than present in the modern-day atmosphere. However, geological evidence seemed to indicate that the atmospheric CO2 concentrations during the Archaean and Proterozoic were far too low to keep the surface from freezing. With a radiative-convective model including new, updated thermal absorption coefficients, we found that the amount of CO2 necessary to obtain 273 K at the surface is reduced up to an order of magnitude compared to previous studies. For the late Archaean and early Proterozoic period of the Earth, we calculate that CO2 partial pressures of only about 2.9 mb are required to keep its surface from freezing which is compatible with the amount inferred from sediment studies. This conclusion was not significantly changed when we varied model parameters such as relative humidity or surface albedo, obtaining CO2 partial pressures for the late Archaean between 1.5 and 5.5 mb. Thus, the contradiction between sediment data and model results disappears for the late Archaean and early Proterozoic.Comment: 53 pages, 4 tables, 11 figures, published in Planetary and Space Scienc

Rapid population decline in migratory shorebirds relying on Yellow Sea tidal mudflats as stopover sites

Migratory animals are threatened by human-induced global change. However, little is known about how stopover habitat, essential for refuelling during migration, affects the population dynamics of migratory species. Using 20 years of continent-wide citizen science data, we assess population trends of ten shorebird taxa that refuel on Yellow Sea tidal mudflats, a threatened ecosystem that has shrunk by >65% in recent decades. Seven of the taxa declined at rates of up to 8% per year. Taxa with the greatest reliance on the Yellow Sea as a stopover site showed the greatest declines, whereas those that stop primarily in other regions had slowly declining or stable populations. Decline rate was unaffected by shared evolutionary history among taxa and was not predicted by migration distance, breeding range size, non-breeding location, generation time or body size. These results suggest that changes in stopover habitat can severely limit migratory populations

Gonadotropin-releasing hormone analogs during chemotherapy for preservation of ovarian function and fertility in premenopausal early breast cancer patients: a systematic review and meta-analysis of individual patient-level data

Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient\u2013level data was conducted to better assess the efficacy and safety of this strategy in patients with early breast cancer. Methods The trials in which premenopausal women with early breast cancer were randomly assigned to receive (neo)adjuvant chemotherapy alone or with concurrent GnRHa were eligible for inclusion. Primary end points were premature ovarian insufficiency (POI) rate and post-treatment pregnancy rate. Disease-free survival and overall survival were secondary end points. Because each study represents a cluster, statistical analyses were performed using a random effects model. Results A total of 873 patients from five trials were included. POI rate was 14.1% in the GnRHa group and 30.9% in the control group (adjusted odds ratio, 0.38; 95% CI, 0.26 to 0.57; P, .001). A total of 37 (10.3%) patients had at least one post-treatment pregnancy in the GnRHa group and 20 (5.5%) in the control group (incidence rate ratio, 1.83; 95% CI, 1.06 to 3.15; P = .030). No significant differences in disease-free survival (adjusted hazard ratio, 1.01; 95% CI, 0.72 to 1.42; P = .999) and overall survival (adjusted hazard ratio, 0.67; 95% CI, 0.42 to 1.06; P = .083) were observed between groups. Conclusion Our findings provide evidence for the efficacy and safety of temporary ovarian suppression with GnRHa during chemotherapy as an available option to reduce the likelihood of chemotherapy-induced POI and potentially improve future fertility in premenopausal patients with early breast cancer

Population Structure of Humpback Whales from Their Breeding Grounds in the South Atlantic and Indian Oceans

Although humpback whales are among the best-studied of the large whales, population boundaries in the Southern Hemisphere (SH) have remained largely untested. We assess population structure of SH humpback whales using 1,527 samples collected from whales at fourteen sampling sites within the Southwestern and Southeastern Atlantic, the Southwestern Indian Ocean, and Northern Indian Ocean (Breeding Stocks A, B, C and X, respectively). Evaluation of mtDNA population structure and migration rates was carried out under different statistical frameworks. Using all genetic evidence, the results suggest significant degrees of population structure between all ocean basins, with the Southwestern and Northern Indian Ocean most differentiated from each other. Effective migration rates were highest between the Southeastern Atlantic and the Southwestern Indian Ocean, followed by rates within the Southeastern Atlantic, and the lowest between the Southwestern and Northern Indian Ocean. At finer scales, very low gene flow was detected between the two neighbouring sub-regions in the Southeastern Atlantic, compared to high gene flow for whales within the Southwestern Indian Ocean. Our genetic results support the current management designations proposed by the International Whaling Commission of Breeding Stocks A, B, C, and X as four strongly structured populations. The population structure patterns found in this study are likely to have been influenced by a combination of long-term maternally directed fidelity of migratory destinations, along with other ecological and oceanographic features in the region

Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.

BACKGROUND: Staphylococcus aureus bacteraemia is a common and frequently fatal infection. Adjunctive rifampicin may enhance early S. aureus killing, sterilise infected foci and blood faster, and thereby reduce the risk of dissemination, metastatic infection and death. OBJECTIVES: To determine whether or not adjunctive rifampicin reduces bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. Secondary objectives included evaluating the impact of rifampicin on all-cause mortality, clinically defined failure/recurrence or death, toxicity, resistance emergence, and duration of bacteraemia; and assessing the cost-effectiveness of rifampicin. DESIGN: Parallel-group, randomised (1 : 1), blinded, placebo-controlled multicentre trial. SETTING: UK NHS trust hospitals. PARTICIPANTS: Adult inpatients (≥ 18 years) with meticillin-resistant or susceptible S. aureus grown from one or more blood cultures, who had received < 96 hours of antibiotic therapy for the current infection, and without contraindications to rifampicin. INTERVENTIONS: Adjunctive rifampicin (600-900 mg/day, oral or intravenous) or placebo for 14 days in addition to standard antibiotic therapy. Investigators and patients were blinded to trial treatment. Follow-up was for 12 weeks (assessments at 3, 7, 10 and 14 days, weekly until discharge and final assessment at 12 weeks post randomisation). MAIN OUTCOME MEASURES: The primary outcome was all-cause bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. RESULTS: Between December 2012 and October 2016, 758 eligible participants from 29 UK hospitals were randomised: 370 to rifampicin and 388 to placebo. The median age was 65 years [interquartile range (IQR) 50-76 years]. A total of 485 (64.0%) infections were community acquired and 132 (17.4%) were nosocomial; 47 (6.2%) were caused by meticillin-resistant S. aureus. A total of 301 (39.7%) participants had an initial deep infection focus. Standard antibiotics were given for a median of 29 days (IQR 18-45 days) and 619 (81.7%) participants received flucloxacillin. By 12 weeks, 62 out of 370 (16.8%) patients taking rifampicin versus 71 out of 388 (18.3%) participants taking the placebo experienced bacteriological (microbiologically confirmed) failure/recurrence or died [absolute risk difference -1.4%, 95% confidence interval (CI) -7.0% to 4.3%; hazard ratio 0.96, 95% CI 0.68 to 1.35; p = 0.81]. There were 4 (1.1%) and 5 (1.3%) bacteriological failures (p = 0.82) in the rifampicin and placebo groups, respectively. There were 3 (0.8%) versus 16 (4.1%) bacteriological recurrences (p = 0.01), and 55 (14.9%) versus 50 (12.9%) deaths without bacteriological failure/recurrence (p = 0.30) in the rifampicin and placebo groups, respectively. Over 12 weeks, there was no evidence of differences in clinically defined failure/recurrence/death (p = 0.84), all-cause mortality (p = 0.60), serious (p = 0.17) or grade 3/4 (p = 0.36) adverse events (AEs). However, 63 (17.0%) participants in the rifampicin group versus 39 (10.1%) participants in the placebo group experienced antibiotic or trial drug-modifying AEs (p = 0.004), and 24 (6.5%) participants in the rifampicin group versus 6 (1.5%) participants in the placebo group experienced drug-interactions (p = 0.0005). Evaluation of the costs and health-related quality-of-life impacts revealed that an episode of S. aureus bacteraemia costs an average of £12,197 over 12 weeks. Rifampicin was estimated to save 10% of episode costs (p = 0.14). After adjustment, the effect of rifampicin on total quality-adjusted life-years (QALYs) was positive (0.004 QALYs), but not statistically significant (standard error 0.004 QALYs). CONCLUSIONS: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S. aureus bacteraemia. FUTURE WORK: Given the substantial mortality, other antibiotic combinations or improved source management should be investigated. TRIAL REGISTRATIONS: Current Controlled Trials ISRCTN37666216, EudraCT 2012-000344-10 and Clinical Trials Authorisation 00316/0243/001. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 59. See the NIHR Journals Library website for further project information.NIHR HTA Programm